Matches in Nanopublications for { ?s ?p "[However, because Navitoclax has a low binding affinity to Mcl-1, anticancer activity by Navitoclax is often attenuated by the elevated expression of Mcl-1 in hepatocellular carcinoma (HCC) and other cancers, posing a serious problem for its potential clinical utilities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- NP549325.RATYejzhwEs9v07xvVi4ZGsPW-jDt9qBoz4F4rAaBS--Y130_assertion description "[However, because Navitoclax has a low binding affinity to Mcl-1, anticancer activity by Navitoclax is often attenuated by the elevated expression of Mcl-1 in hepatocellular carcinoma (HCC) and other cancers, posing a serious problem for its potential clinical utilities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP549325.RATYejzhwEs9v07xvVi4ZGsPW-jDt9qBoz4F4rAaBS--Y130_provenance.
- NP1071672.RA_GhGvv5pqTLIgFxP6thx9Gt_llx8K0YkLfdNg9s-Pf4130_assertion description "[However, because Navitoclax has a low binding affinity to Mcl-1, anticancer activity by Navitoclax is often attenuated by the elevated expression of Mcl-1 in hepatocellular carcinoma (HCC) and other cancers, posing a serious problem for its potential clinical utilities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1071672.RA_GhGvv5pqTLIgFxP6thx9Gt_llx8K0YkLfdNg9s-Pf4130_provenance.